sellModerate cluster of 710b5-1 plan
Lawrence J. Hineline sold $926k of ITCI
SVP of Finance, CFO at Intra-Cellular Therapies, Inc.. 13,337 shares at an average of $69.43, traded Feb 26, 2024, filed Feb 27, 2024.
Warning score
46Value
$926k
13,337 shares
Holdings after
0
-179% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +22RoleCFO
- +24Trade size$926k at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster7 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-021569, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 23, 2024 | MOption exercise Common Stock10b5-1 | +7,455 | - | - | 7,455 | Feb 27, 2024 |
| Feb 26, 2024 | SOpen-market sale Common Stock10b5-1 | -300 | $68.33 | $20k | 7,155 | Feb 27, 2024 |
| Feb 26, 2024 | SOpen-market sale Common Stock10b5-1 | -6,867 | $69.38 | $476k | 288 | Feb 27, 2024 |
| Feb 26, 2024 | SOpen-market sale Common Stock10b5-1 | -288 | $70.15 | $20k | 0 | Feb 27, 2024 |
| Feb 26, 2024 | MOption exercise Common Stock10b5-1 | +5,882 | $36.89 | $217k | 5,882 | Feb 27, 2024 |
| Feb 26, 2024 | SOpen-market sale Common Stock10b5-1 | -5,282 | $69.47 | $367k | 600 | Feb 27, 2024 |
| Feb 26, 2024 | SOpen-market sale Common Stock10b5-1 | -600 | $69.81 | $42k | 0 | Feb 27, 2024 |
| Feb 23, 2024 | MOption exercise Restricted Stock Unitsderivative10b5-1 | -7,455 | $0.00 | $0 | 0 | Feb 27, 2024 |
| Feb 26, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,882 | $0.00 | $0 | 0 | Feb 27, 2024 |
Related signals
Other insiders at Intra-Cellular Therapies, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $8.7M 102,697 shares | -9% | |
| 30Weak | Intra-Cellular Therapies, Inc. | Michael Halstead President | $3.7M 41,583 shares | -182% | |
| 23Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $5.1M 70,000 shares | -6% | |
| 23Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $7.1M 95,925 shares | -9% | |
| 28Weak | Intra-Cellular Therapies, Inc. | Sharon Mates Chairman and CEO | $9.1M 121,073 shares | -11% | |
| 43Moderate | Intra-Cellular Therapies, Inc. | Mark Neumann EVP, Chief Commercial Officer | $1.4M 18,714 shares | -39% | |
| 23Weak | Intra-Cellular Therapies, Inc. | Rory B Riggs director | $337k 4,462 shares | -4% | |
| 33Weak | Intra-Cellular Therapies, Inc. | Robert L Van Nostrand director | $1.5M 20,000 shares | -67% | |
| 25Weak | Intra-Cellular Therapies, Inc. | Suresh K. Durgam EVP, Chief Medical Officer | $673k 10,162 shares | -45% | |
| 40Moderate | Intra-Cellular Therapies, Inc. | Michael Halstead EVP and General Counsel | $1.4M 20,477 shares | -156% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.